Patrick Hess
Overview
Explore the profile of Patrick Hess including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
43
Citations
963
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Renneberg D, Hubler F, Rey M, Hess P, Delahaye S, Gatfield J, et al.
Bioorg Med Chem Lett
. 2015 Aug;
25(18):3941-6.
PMID: 26231163
Chemical evolution of mibefradil resulted in the identification of novel bridged tetrahydronaphthalene derivatives as potent T/L-type calcium channel blockers. A SAR study, in vitro and in vivo DMPK properties as...
12.
Iglarz M, Landskroner K, Bauer Y, Vercauteren M, Rey M, Renault B, et al.
J Cardiovasc Pharmacol
. 2015 Aug;
66(5):457-67.
PMID: 26230396
Aims: We compared the efficacy of macitentan, a novel dual endothelin A/endothelin B receptor antagonist, with that of another dual endothelin receptor antagonist, bosentan, in a rat model of non-vasoreactive...
13.
Iglarz M, Steiner P, Wanner D, Rey M, Hess P, Clozel M
J Cardiovasc Pharmacol
. 2015 May;
66(4):332-7.
PMID: 25992919
Introduction: The goal of this study was to characterize the role of Endothelin (ET) type B receptors (ETB) on vascular function in healthy and diseased conditions and demonstrate how it...
14.
Surivet J, Zumbrunn C, Rueedi G, Bur D, Bruyere T, Locher H, et al.
J Med Chem
. 2014 Dec;
58(2):927-42.
PMID: 25494934
Novel antibacterial drugs that are effective against infections caused by multidrug resistant pathogens are urgently needed. In a previous report, we have shown that tetrahydropyran-based inhibitors of bacterial type II...
15.
Bauer Y, Tedrow J, de Bernard S, Birker-Robaczewska M, Gibson K, Guardela B, et al.
Am J Respir Cell Mol Biol
. 2014 Jul;
52(2):217-31.
PMID: 25029475
The bleomycin-induced rodent lung fibrosis model is commonly used to study mechanisms of lung fibrosis and to test potential therapeutic interventions, despite the well recognized dissimilarities to human idiopathic pulmonary...
16.
Treiber A, Aanismaa P, de Kanter R, Delahaye S, Treher M, Hess P, et al.
J Pharmacol Exp Ther
. 2014 Apr;
350(1):130-43.
PMID: 24769543
Treatment of pulmonary arterial hypertension with the endothelin receptor antagonist bosentan has been associated with transient increases in liver transaminases. Mechanistically, bosentan inhibits the bile salt export pump (BSEP) leading...
17.
Iglarz M, Bossu A, Wanner D, Bortolamiol C, Rey M, Hess P, et al.
Life Sci
. 2014 Mar;
118(2):333-9.
PMID: 24582812
Aims: The endothelin (ET) system is a tissular system, as the production of ET isoforms is mostly autocrine or paracrine. Macitentan is a novel dual ETA/ETB receptor antagonist with enhanced...
18.
Bolli M, Abele S, Birker M, Bravo R, Bur D, de Kanter R, et al.
J Med Chem
. 2013 Dec;
57(1):110-30.
PMID: 24367923
In preceding communications we summarized our medicinal chemistry efforts leading to the identification of potent, selective, and orally active S1P1 agonists such as the thiophene derivative 1. As a continuation...
19.
Bolli M, Velker J, Muller C, Mathys B, Birker M, Bravo R, et al.
J Med Chem
. 2013 Dec;
57(1):78-97.
PMID: 24345087
Previously, we reported on the discovery of a novel series of bicyclo[3.1.0]hexane fused thiophene derivatives that serve as potent and selective S1P1 receptor agonists. Here, we discuss our efforts to...
20.
Bolli M, Muller C, Mathys B, Abele S, Birker M, Bravo R, et al.
J Med Chem
. 2013 Nov;
56(23):9737-55.
PMID: 24266709
From a high-throughput screening campaign aiming at the identification of novel S1P1 receptor agonists, the pyrazole derivative 2 emerged as a hit structure. Medicinal chemistry efforts focused not only on...